{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"Harrow Sells Non-Ophthalmic Compounding Business - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"KaAErIc3ZV\"><a href=\"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/\">Harrow Sells Non-Ophthalmic Compounding Business<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/embed\/#?secret=KaAErIc3ZV\" width=\"600\" height=\"338\" title=\"&#8220;Harrow Sells Non-Ophthalmic Compounding Business&#8221; &#8212; Pharma Trend\" data-secret=\"KaAErIc3ZV\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"NASHVILLE, Tenn.&#8211;(BUSINESS WIRE)&#8211;$HROW&#8211;Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non\u2011ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (\u201cRevelation\u201d). Pursuant to the terms of the transaction, Revelation purchased the assets of Harrow\u2019s ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg"}